Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.32 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23472264 | 0.82 | TLR8 (0.33) | STK17BSTK17AMERTKTLR8 | |
| SCHEMBL15469754 | 0.78 | HTR2A (0.37) | STK17BSTK17AMERTKTLR8 | |
| SCHEMBL13195087 | 0.77 | STK17B (0.41) | STK17BSTK17AMERTKCHRNB2CHRNB4 | |
| SCHEMBL13195019 | 0.77 | TLR7 (0.46) | TLR8 | |
| SCHEMBL20219294 | 0.75 | TLR8 (0.31) | STK17BSTK17ATLR8 | |
| SCHEMBL15469710 | 0.73 | TLR8 (0.39) | STK17BSTK17AMERTKTLR8 | |
| SCHEMBL20219250 | 0.73 | STK17B (0.40) | STK17BSTK17AMERTKTLR8 | |
| SCHEMBL20219544 | 0.72 | PGK1 (0.33) | STK17BSTK17A | |
| SCHEMBL13195671 | 0.72 | TLR7 (0.39) | — | |
| SCHEMBL15469708 | 0.71 | TLR8 (0.44) | TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10780089-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2020-09-22 | — | — | US | disclosed |
| US-20200061059-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10780089-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | STK17B 1962/4885STK17A 2004/4885MERTK 861/4885 |
| US-20200061059-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | STK17B 1962/4885STK17A 2004/4885MERTK 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.